Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome (34-DAP)

Expanded access is no longer available for this treatment.
Sponsor:
Information provided by (Responsible Party):
The Cleveland Clinic
ClinicalTrials.gov Identifier:
NCT01373333
First received: June 13, 2011
Last updated: July 18, 2016
Last verified: July 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: Expanded access is no longer available for this treatment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)